Dennis Slamon（丹尼斯·史莱门）

医学教授  肿瘤学家 改革了乳腺癌的治疗方法

他确保转译正常进行

Dennis Slamon有个想法。既然基因学在有些癌症治疗中占有重要地位，那么基因靶向药物应该能够治疗疾病。1987年，他将基因科技（Genentech）的HER2抗体和一个特别具侵略性的乳腺癌配对，该疾病困扰着世界上15-20%的女性。经过多年的研究，先在有盖培养皿中培养细胞，在老鼠身上试验，Slamon已经准备好进行临床试验了。在那个时候，他遇到了Barbara Bradfield，她的乳腺癌细胞已经开始转移了。他请求她成为这种药的第一位临床实验病人，这种药后来命名为“赫赛汀”。对Bradfield来说，这就是一种神奇的药：20多年后，她依然在世，而癌症也痊愈了。赫赛汀在1998年获得美国食品和药物管理局（FDA）的认证，它将曾经最致命形式的乳腺癌变为最易治愈的癌症之一。转化医学（将研究变为有效地治疗）依然是Slamon研究的重点对象。

Dennis Slamon

Professor of Medicine

He made sure nothing got lost in translation.

Dennis Slamon had an idea. Since genetics plays a role in some cancers, a genetically targeted drug could arrest the disease. In 1987, he matched Genentech’s HER2 antibody with a particularly aggressive form of breast cancer that affects about 15 to 20 percent of women. After years of research, treating cells in a petri dish and then in mice, Slamon was ready for clinical trials. That’s when his path crossed that of Barbara Bradfield, a woman whose breast cancer had already metastasized. He begged Bradfield to become part of the first clinical trial of the drug that would be dubbed Herceptin. For Bradfield, it would be a miracle drug: more than 20 years later, she is still alive and cancer-free. And Herceptin, approved by the FDA in 1998, has transformed one of the deadliest forms of breast cancer into one of the most treatable. Translational medicine – turning basic research into effective treatment – is still Slamon’s focus.